Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled XW001 for Hospitalized COVID-19
NCT05083117Phase 2Withdrawn
- Sponsor
- Sciwind Biosciences
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of xw001 in coronavirus disease 2019 (COVID-19), sponsored by Sciwind Biosciences. Planned start Oct 2021; status: withdrawn.
02
Drugs
xw001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05083117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083117.